Investment Type: Venture Capital
Investment Stage: Series A
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 17.07.2017 | Enterin In... | enterininc.com | $12.7M | United Sta... |
Mentions in press and media 6
| Date | Title | Description |
| 30.06.2020 | ADC THERAPEUTICS SA ADC Therapeutics : New Ventures Portfolio Company, ADC Therapeutics, Completes $267 Million IPO | VIRGINIA BEACH, Va., June 30, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of its portfolio company, ADC Therapeutics (NYSE:AD... |
| 25.06.2020 | New Ventures Portfolio Company, Royalty Pharma, Surges On Public Debut | VIRGINIA BEACH, Va., June 25, 2020 /PRNewswire/ -- New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, is pleased to announce the IPO of one of its portfolio companies, Royalty Pharma (... |
| 25.11.2019 | New Ventures closes $90M for its Third Fund to invest in early to mid-stage healthcare and digital medicine startups | New Ventures, a venture capital firm that invest in healthcare companies, has raised a total of $90 million for its firm’s third fund, New Ventures III. Founded by a group of co-founders and entrepreneurial operators, New Ventures III follo... |
| 15.02.2018 | New Ventures III Leads $5M Series A for Transparency Life Sciences | Transparency Life Sciences (TLS), a pioneer in digital drug development clinical services, today announced completion of a $5.0 million Series A financing led by venture investor New Ventures III. Existing private investors also participate... |
| 15.02.2018 | Transparency Life Sciences Raises $5.0 Million Series A | Transparency Life Sciences (TLS), a pioneer in digital drug development clinical services, today announced completion of a $5.0 million Series A financing led by venture investor New Ventures III. Existing private investors also participate... |
| 17.07.2017 | Enterin Raises $12.7M Series A from New Ventures | Enterin Inc., a Philadelphia-based biotechnology company developing novel compounds to treat Parkinson's disease (PD), today announced the completion of a $12.7 million Series A financing round. The financing included new investors New Vent... |